| Literature DB >> 29924445 |
Farzad Khademi1,2, Amirhossein Sahebkar3,4,5, Mahdi Fasihi-Ramandi6, Ramezan Ali Taheri2.
Abstract
A promising strategy for preventing illness and death caused by Mycobacterium tuberculosis (Mtb) is vaccination. In this study, we aimed to evaluate the capacity of a multicomponent vaccine comprising HspX/EsxS-fused protein, PLGA (poly (lactide-co-glycolide)) and DOTAP (1, 2-dioleoyl-3-trimethylammonium propane) in eliciting immune responses against Mtb in BALB/c mice. A preparation of PLGA nanoparticles (NPs) containing fused protein and DOTAP adjuvant was made using double emulsion solvent evaporation (w/o/w) and lipid film hydration methods, respectively. After three subcutaneous immunization of BALB/c mice with various formulations, ELISA technique was used to measure interferon-γ (IFN-γ) and interleukin-4 (IL-4) cytokines levels in splenocytes as well as serum anti-HspX/EsxS IgG1 and IgG2a titers. The results of the current study showed that PLGA/HspX/EsxS/DOTAP formulation was able to induce higher levels of FN-γ, IgG1, and IgG2a responses compared with BCG as the positive control, HspX/EsxS, HspX/EsxS/DOTAP and PLGA/HspX/EsxS formulations. Our results suggest that PLGA NPs, as delivery system, and DOTAP, as adjuvant, have a good potential to enhance immune responses against HspX/EsxS antigen after subcutaneous immunization of BALB/c mice.Entities:
Keywords: zzm321990Mycobacterium tuberculosiszzm321990; DOTAP; HspX/EsxS; PLGA; immune responses
Mesh:
Substances:
Year: 2018 PMID: 29924445 DOI: 10.1111/apm.12851
Source DB: PubMed Journal: APMIS ISSN: 0903-4641 Impact factor: 3.205